New Sickle Cell Drugs Offer ‘Welcome’ But Costly Options

with Chart: Current Market Access to Sickle Cell Disease Medications

Dec 26, 2019

The first targeted therapy to treat pain crises in people with sickle cell disease, which was recently approved by the FDA, presents a “welcome” new option that payers likely will embrace, a PBM head tells AIS Health. While the drug’s manufacturer cites “positive” early discussions with payers on it, some experts note the lifetime treatment — via a monthly intravenous infusion — is costly: around $100,000 annually.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.